Leveraging Salmonella typhi Ty21a to activate innate and adaptive immune responses against cancer cells
Socium Therapeutics is developing an orally administered immunotherapy platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s platform – CReST (Cross-presenting Recombinant Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells.

Contact

Get InTouch

Email:

info@sociumtherapeutics.com

Phone:

(973) 585-6202

Address:

90 E. Halsey Road
Suite 311
Parsippany, NJ 07054